Citation Impact
Citing Papers
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
2005
Dysfunctional Transforming Growth Factor-β Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model
2009
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis
2006
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
MicroRNA Expression Profiling in Prostate Cancer
2007
Circulating microRNAs as stable blood-based markers for cancer detection
2008 Standout
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
2004 Standout
Stress-induced transcription of satellite III repeats
2003
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
External Quality Assurance of HER2 FISH and ISH Testing
2008
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Basal cell carcinomas: attack of the hedgehog
2008 Standout
Gene amplification and overexpression of HER2 in renal cell carcinoma
2002
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Arresting a Transient Receptor Potential (TRP) Channel
2010 StandoutNobel
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
A UK NEQAS ISH Multicenter Ring Study Using the Ventana HER2 Dual-Color ISH Assay
2010
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
2005 StandoutNature
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
Smad transcription factors
2005 Standout
Determination ofHER2Amplification by In Situ Hybridization
2008
The emerging role of lncRNAs in cancer
2015 Standout
Molecular determinants of resistance to antiandrogen therapy
2003 Standout
Arrestin Development: Emerging Roles for β-arrestins in Developmental Signaling Pathways
2009 StandoutNobel
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH
2010
Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
2000
Antibody therapy of cancer
2012 Standout
Therapeutic potential of β-arrestin- and G protein-biased agonists
2010 StandoutNobel
Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms.
1996
Testicular germ-cell tumours in a broader perspective
2005 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
2015 Standout
Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling
2011 StandoutNobel
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Androgen action and metabolism in prostate cancer
2012
Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study
2002 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Cancer immunotherapy comes of age
2011 StandoutNature
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Antibody and T‐cell responses specific for the androgen receptor in patients with prostate cancer
2007
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
2020 Standout
The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network
2019
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
2005
Prostate epithelial stem cells
2005
The Androgen Receptor Represses Transforming Growth Factor-β Signaling through Interaction with Smad3
2002
Targeting the androgen receptor pathway in prostate cancer
2008
Transient Receptor Potential Cation Channels in Disease
2007 Standout
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
2018
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
2010
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
β-arrestin-mediated receptor trafficking and signal transduction
2011 StandoutNobel
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
2009 StandoutNature
Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
2021
Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer
2004
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
2017 StandoutNobel
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer
2006 Standout
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells
2007
Bladder Cancer
2020 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The evolution of antiandrogens: MDV3100 comes of age
2012
The Interleukin-8 Pathway in Cancer
2008 Standout
Overcoming mutation-based resistance to antiandrogens with rational drug design
2013
Multigene Reverse Transcription-PCR Profiling of Circulating Tumor Cells in Hormone-Refractory Prostate Cancer
2004
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
2006
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.
2003
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
2011 Standout
Localization of Type 5 17β-Hydroxysteroid Dehydrogenase, 3β-Hydroxysteroid Dehydrogenase, and Androgen Receptor in the Human Prostate by in Situ Hybridization and Immunocytochemistry
1999
An Updated Definition of Stroke for the 21st Century
2013 Standout
Androgen Receptor Overexpression in Prostate Cancer Linked to Purα Loss from a Novel Repressor Complex
2008
Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancer
2009
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
2019 Standout
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
The Will Rogers Phenomenon in Urological Oncology
2007
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression
2012
Works of Ken Grigor being referenced
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
2003
Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer
2002
Marker tumour response to Evans and Pasteur bacilie Calmette‐Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)
1994
Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder
2000
Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
1998
The localisation and expression of 5 alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures
1998
HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
2003
Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer
2005
Trends in Reporting Gleason Score 1991 to 2001: Changes in the Pathologist's Practice
2004
Should the Contralateral Testis BeBiopsied? Round Table Discussion
1993
Is Chromosome 9 Loss a Marker of Disease Recurrence in Transitional Cell Carcinoma of the Urinary Bladder?
1999
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
2003